218 related articles for article (PubMed ID: 22854051)
1. Severe hypocalcemia following denosumab injection in a hemodialysis patient.
McCormick BB; Davis J; Burns KD
Am J Kidney Dis; 2012 Oct; 60(4):626-8. PubMed ID: 22854051
[TBL] [Abstract][Full Text] [Related]
2. The RANKL pathway and denosumab.
Dore RK
Rheum Dis Clin North Am; 2011 Aug; 37(3):433-52, vi-vii. PubMed ID: 22023901
[TBL] [Abstract][Full Text] [Related]
3. Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency.
Ungprasert P; Cheungpasitporn W; Srivali N; Kittanamongkolchai W; Bischof EF
Am J Emerg Med; 2013 Apr; 31(4):756.e1-2. PubMed ID: 23399342
[TBL] [Abstract][Full Text] [Related]
4. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
5. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
6. [Denosumab for bone metastasis of thoracic tumors-preparation of a practice manual and evaluation of its effectiveness].
Kondo Y; Tamiya M; Hirashima T; Ryota N; Sando M; Iwata K; Okamoto N; Suzuki H; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Tsuboi T; Yamato A; Shimura K; Kawase I
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1391-5. PubMed ID: 25434441
[TBL] [Abstract][Full Text] [Related]
7. Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature.
Dusilova Sulkova S; Horacek J; Safranek R; Gorun P; Viklicky O; Palicka V
Acta Medica (Hradec Kralove); 2014; 57(1):30-3. PubMed ID: 25006661
[TBL] [Abstract][Full Text] [Related]
8. [Preliminary results of an open-label observational study evaluating the efficacy and safety of Prolia used in women with postmenopausal osteoporosis].
Ershova OB; Lesniak OM; Belova KIu; Nazarova AV; Manovitskaia AV; Musaeva TM; Musraev RM; Nurlygaianov RZ; Rozhinskaia LIa; Skripnikova IA; Toroptsova NV
Ter Arkh; 2014; 86(10):60-4. PubMed ID: 25509894
[TBL] [Abstract][Full Text] [Related]
9. Denosumab for the treatment of osteoporosis and cancer-related conditions.
Lewiecki EM; Bilezikian JP
Clin Pharmacol Ther; 2012 Jan; 91(1):123-33. PubMed ID: 22158568
[TBL] [Abstract][Full Text] [Related]
10. Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.
Sutton EE; Riche DM
Ann Pharmacother; 2012; 46(7-8):1000-9. PubMed ID: 22837347
[TBL] [Abstract][Full Text] [Related]
11. Denosumab--an emerging treatment for postmenopausal osteoporosis.
Lewiecki EM
Expert Opin Biol Ther; 2010 Mar; 10(3):467-76. PubMed ID: 20095877
[TBL] [Abstract][Full Text] [Related]
12. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
13. [Denosumab for treatment of postmenopausal osteoporosis].
Syversen U; Halse JI; Geisler J; Eriksen EF
Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295
[TBL] [Abstract][Full Text] [Related]
14. The clinical use of denosumab for the management of low bone mineral density in postmenopausal women.
Harris KB; Nealy KL; Jackson DJ; Thornton PL
J Pharm Pract; 2012 Jun; 25(3):310-8. PubMed ID: 22550161
[TBL] [Abstract][Full Text] [Related]
15. Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial.
Hiramatsu R; Ubara Y; Sawa N; Hoshino J; Hasegawa E; Kawada M; Imafuku A; Sumida K; Mise K; Hayami N; Suwabe T; Takaichi K
Am J Kidney Dis; 2015 Jul; 66(1):175-7. PubMed ID: 25979349
[No Abstract] [Full Text] [Related]
16. Identification of the risk factors associated with hypocalcemia induced by denosumab.
Okada N; Kawazoe K; Teraoka K; Kujime T; Abe M; Shinohara Y; Minakuchi K
Biol Pharm Bull; 2013; 36(10):1622-6. PubMed ID: 23934346
[TBL] [Abstract][Full Text] [Related]
17. Denosumab update.
Lewiecki EM
Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
[TBL] [Abstract][Full Text] [Related]
18. Treatment of osteoporosis with denosumab.
Lewiecki EM
Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
[TBL] [Abstract][Full Text] [Related]
19. Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report.
Park SY; Kim J; Chung HY
Osteoporos Int; 2022 Jan; 33(1):305-308. PubMed ID: 34232341
[TBL] [Abstract][Full Text] [Related]
20. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
Bruhn C
Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
